enzalutamide + abiraterone acetate + prednisone
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Castration-Resistant Prostate Cancer
Conditions
Metastatic Castration-Resistant Prostate Cancer
Trial Timeline
Jul 9, 2012 → Jan 4, 2018
NCT ID
NCT01650194About enzalutamide + abiraterone acetate + prednisone
enzalutamide + abiraterone acetate + prednisone is a phase 2 stage product being developed by Astellas Pharma for Metastatic Castration-Resistant Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01650194. Target conditions include Metastatic Castration-Resistant Prostate Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Castration-Resistant Prostate Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01650194 | Phase 2 | Completed |
Competing Products
20 competing products in Metastatic Castration-Resistant Prostate Cancer